Interim safety results from a phase II/III trial with 5-FU, oxaliplatin, and docetaxel (FLOT) versus epirubicin, cisplatin, and 5-FU (ECF) in patients with locally advanced, resectable gastric/oesophagogastric junction (OGJ) cancer: A study of the AIO.
Ulrike Koock
No relevant relationships to disclose
Claudia Pauligk
No relevant relationships to disclose
Kim Barbara Luley
No relevant relationships to disclose
Frank Mayer
No relevant relationships to disclose
Karsten Schulmann
Honoraria - Amgen; AstraZeneca; Falk Pharmaceuticals; Merck Serono
Other Remuneration - Merck Serono; Novartis; Pfizer
Nils Homann
No relevant relationships to disclose
Harald Schmalenberg
No relevant relationships to disclose
Wael Hozaeel
No relevant relationships to disclose
Ralf Hofheinz
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Stephan Probst
No relevant relationships to disclose
Rolf Mahlberg
No relevant relationships to disclose
Michael Koenigsmann
No relevant relationships to disclose
Georg Martin Haag
No relevant relationships to disclose
Johannes Meiler
No relevant relationships to disclose
Nicole Prasnikar
No relevant relationships to disclose
Dirk M. Behringer
No relevant relationships to disclose
Jorg Trojan
No relevant relationships to disclose
Matthias Egger
No relevant relationships to disclose
Elke Jäger
No relevant relationships to disclose
Salah-Eddin Al-Batran
No relevant relationships to disclose